Mesoblast stock

MSB · ASX · AUD

Compare Mesoblast
$1.70Change from previous close: −0.59%Absolute change: −$0.01

Close · November 20, 2026

Price history

−26.30% over the period

1 year: from $2.30 (November 20, 2025) to $1.70 (November 20, 2026), −26.30%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026$1.70
October 30, 2026$2.26
September 30, 2026$2.11
August 31, 2026$2.36
July 31, 2026$2.05
June 30, 2026$1.96
May 29, 2026$2.14
April 30, 2026$2.12
March 31, 2026$2.16
February 27, 2026$2.24
January 30, 2026$2.53
December 31, 2025$2.72
November 28, 2025$2.71
November 20, 2025$2.30

At a glance

  • The company

    Develops regenerative medicine products based on mesenchymal lineage cells, such as Ryoncil, for inflammatory and heart diseases

  • Latest results

    Quarter to June 30, 2026 · EPS -$0.01 (estimate $0.00)

TickerLandia's take on Mesoblast

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$1.69
52-wk high$3.31

−48.79% from the 52-week high

Analysts · 5 analysts

Average target$3.51+106.88% vs. price

Buy 5 · Hold 0 · Sell 0

TickerLandia Fingerprint: Mesoblast

Compared with similar companies: very low earnings stability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Mesoblast is pricier than similar companies

Mesoblast's Forward P/E: 82.4, +128% against the median of a group of 9 similar companies (36.1).

Compared with 9 similar companies

Mesoblast's metrics compared with similar companies
MetricMesoblastPosition in the groupBand
Forward P/E82.4High
Operating margin-42.6%Low
ROE-9.9%Low
Debt/equity0.22Middle
Price/book2.74Middle

Grey band: the middle half of the group; tick: the median; dot: Mesoblast. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$68.91M

Latest quarter · Q2 2026

Net income

-$17.34M

Latest quarter · Q2 2026

Quarterly net margin

-25.2%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$2.21B
EPS
-$0.07
Volume
4.88M
Daily trading
€4.23M
Dividend yield
0.00%

How Mesoblast is changing

All results
  • Revenue grew 74.5% a year on average over the last 5 years

  • Operating margin rose from −923.7% to −42.6%

  • Shares outstanding up 114.0% in 5 years

Returns

Mesoblast returns

$1,000 invested in Mesoblast 5 years ago, on November 22, 2021, would be worth $1,064 today: +6.41% in total, +1.25% per year. This is the price return only: dividends are excluded.

PeriodMesoblastS&P/ASX 200$1,000 becomes
1 month−3.69%−2.54%$963
6 months−14.82%+1.13%$852
Year to date−37.68%−1.40%$623
1 year−26.30%+0.47%$737
3 years+389.78%+21.74%$4,898
5 years+6.41%+16.86%$1,064
10 years+48.63%+60.57%$1,486

Over the last 6 months it has done better than 10% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Mesoblast: technical analysis

Mesoblast is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 81.9% below its all-time closing high ($9.38, October 24, 2011).

Trend
Downward
RSI (14 sessions)
34
Between 30 and 70
vs 200-session average
−20.73%

Active signals

  • New 52-week low.

    since November 19, 2026

Support and resistance

Price areas where Mesoblast has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$2.08+22.42%2 touches, last on October 12, 2026
  2. Resistance$2.00+18.09%3 touches, last on September 16, 2026
  3. Resistance$1.93+13.89%6 touches, last on July 10, 2026
  4. Last price$1.70
  5. No support below: the price is near the lows of the year

Volatility and risk

Over the last year it has moved more than the S&P/ASX 200.

Beta (1 year) vs S&P/ASX 200
1.40
Volatility (60 sessions, annualised)
65.2%
Largest fall in the last year
−44.79%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Mesoblast: seasonality

Average monthly price change over 22 years

+3.3%Jan+2.2%Feb+4.1%Mar+8.3%Apr+0.5%May−6.0%Jun+9.0%Jul−3.4%Aug+5.3%Sep+0.5%Oct+5.2%Nov+2.4%Dec

Over the last 22 years, the strongest month for Mesoblast has been July: +9.03% on average, positive in 16 years out of 22. The weakest has been June: −5.99% on average, positive in 6 years out of 22. November, the current month, has been positive in 13 years out of 21 (+5.22% on average).

Show chart data
MonthAverageMedianPositive years
January+3.26%+1.49%13 of 22
February+2.22%+2.09%13 of 22
March+4.09%−0.10%11 of 22
April+8.29%−4.11%7 of 22
May+0.50%+0.60%12 of 22
June−5.99%−4.26%6 of 22
July+9.03%+4.26%16 of 22
August−3.38%−5.91%9 of 22
September+5.25%+0.14%11 of 22
October+0.47%+0.10%11 of 22
November+5.22%+3.99%13 of 21
December+2.35%+1.03%12 of 21

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Mesoblast and its competitors

Melbourne-based Mesoblast has existed since 2004 and works on regenerative medicine products in Australia. Its platform relies on mesenchymal lineage cells, and the portfolio includes Ryoncil, aimed at graft versus host disease in children and at inflammatory bowel conditions, Revascor for hypoplastic left heart syndrome, and remestemcel-L, which is in Phase III trials for heart failure and degenerative back pain. The pipeline also includes MPC-300-IV for rheumatoid arthritis and MPC-25-IC for acute myocardial infarction.

Headquarters
Melbourne, Australia
Employees
108
Founded
2004
Chief executive
Silviu Itescu
Mesoblast and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
MesoblastMSB$1.48B-42.6%—−14.82%
Neuren PharmaceuticalsNEU$1.83B19.9%144.0+68.84%
Metis TechBio7666$1.11B-131.2%—−63.08%
InSilico Medicine Cayman TopCo3696$2.59B-6.9%—−36.46%
Telix PharmaceuticalsTLX$2.92B6.2%92.3−7.71%
3SBio1530$4.56B60.3%3.90−34.08%

Same industry or related industries, similar size. Compare Mesoblast with its competitors · Full profile